HOOKIPA Pharma Inc.

HOOK

US43906K2096

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:31:07 13/01/2026 pm IST			5-day change	1st Jan Change
0.9180 ^USD	+1.10%		+3.15%	+2.80%

31/25/31	Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences	MT
12/25/12	HOOKIPA Pharma Inc.(NasdaqCM:HOOK) dropped from S&P TMI Index	CI

HOOKIPA Pharma Names Julie O'Neill Nonexecutive Chair

Published on 08/30/2024 at 06:02 pm IST - Modified on 08/30/2024 at 06:03 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about HOOKIPA Pharma Inc.

31/25/31	Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences	MT
12/25/12	HOOKIPA Pharma Inc.(NasdaqCM:HOOK) dropped from S&P TMI Index	CI
07/25/07	HOOKIPA Pharma Inc.(NasdaqCM:HOOK) dropped from NASDAQ Composite Index	CI
19/25/19	Hookipa Pharma to Voluntarily Delist From Nasdaq	MT
19/25/19	Hookipa Pharma announces intention to voluntarily delist and deregister its common stock	RE
23/25/23	Sector Update: Health Care Stocks Softer Late Afternoon	MT
22/25/22	Sector Update: Health Care Stocks Retreat Thursday Afternoon	MT
22/25/22	HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise	MT
16/25/16	HOOKIPA Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
20/25/20	Immuneering Names Dr. Igor Matushansky, MD, PhD, as Chief Medical Officer	CI
28/25/28	HOOKIPA Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
21/25/21	Retailers lift FTSE 100 after strong sales tonic	AN
21/25/21	Poolbeg Pharma Says Hookipa Ended Takeover Talks	MT
21/25/21	FTSE 100 flat as UK data keeps pound above USD1.26	AN
21/25/21	Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger	RE
21/25/21	Hookipa Pharma rules out making offer for Poolbeg Pharma	AN
20/25/20	Poolbeg Pharma PLC cancelled the acquisition of HOOKIPA Pharma Inc. in a reverse merger transaction.	CI
30/25/30	Poolbeg Pharma Extends Deadline for Hookipa Pharma Takeover Talks	MT
10/25/10	HC Wainwright Downgrades HOOKIPA Pharma to Neutral From Buy	MT
07/25/07	Hookipa Shareholder Gilead Sciences to Back Poolbeg Merger	MT
02/25/02	Pound sinks but FTSE 100 starts 2025 with a bang	AN
02/25/02	Hookipa Pharma, Poolberg Pharma in Discussions for All-Stock Merger	MT
02/25/02	Poolbeg Pharma in Talks with Hookipa for Potential Combination	MT
02/25/02	HOOKIPA Pharma Inc. announced that it expects to receive $30 million in funding	CI
02/25/02	Poolbeg Pharma PLC entered into non-binding discussions to acquire HOOKIPA Pharma Inc. for $30.2 million in a reverse merger transaction.	CI

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Companyâs replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company